Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model.

Abstract

Metastatic melanoma is a life-threatening disease for which no effective treatment is currently available. In melanoma cells, Rho overexpression promotes invasion and metastasis. However, the effect of statins on spontaneous metastasis and tumor growth remains unclear. In the present study, we investigated the mechanism of statin-mediated tumor growth and metastasis inhibition in an in vivo model. We found that statins significantly inhibited spontaneous metastasis and tumor growth. Statins inhibited the mRNA expression and enzymatic activities of matrix metalloproteinases (MMPs) in vivo and also suppressed the mRNA and protein expression of very late antigens (VLAs). Moreover, statins inhibited the prenylation of Rho as well as the phosphorylation of LIM kinase, serum response factor (SRF), and c-Fos downstream of the Rho signaling pathway. In addition, statins enhanced p53, p21, and p27 expression and reduced phosphorylation of cyclin-dependent kinase and expression of cyclin D1 and E2. These results indicate that statins suppress Rho signaling pathways, thereby inhibiting tumor metastasis and growth. Furthermore, statins markedly improved the survival rate in a metastasis model, suggesting that statins have potential clinical applications for the treatment of metastatic cancers.

• Authors: Masanobu Tsubaki, Tomoya Takeda, Toshiki Kino, Naoya Obata, Tatsuki Itoh, Motohiro Imano, Kenji Mashimo, Daichiro Fujiwara, Katsuhiko Sakaguchi, Takao Satou, Shozo Nishida
• Journal: American journal of cancer research (Am J Cancer Res) Vol. 5 Issue 10 Pg. 3186-97 ( 2015) ISSN: 2156-6976 [Print] United States
• PMID: 26693069 (Publication Type: Journal Article)